ERAS today
$15.78-$1.02 (-6.07%)close Nov 12, 2026Trend
DailyDowntrend (starting)
4 hourAscending Triangle
1 hourStrong Bullish
15 minStrong Bullish
5 minStrong Bullish
Daily trend turns up above $24.28
Key levels
Resistance$18.77
Resistance$16.88
Support$15.38
Support$13.11
Latest news & SEC filings
ProductTango Therapeutics and Erasca Start Combination Clinical Trial
All ERAS news →About Erasca
Erasca develops medicines for cancer patients whose tumors carry changes in the RAS/MAPK signaling pathway. Its two most advanced drug candidates are an experimental pan-RAS molecular glue and an experimental pan-KRAS inhibitor, both in early human testing, plus a preclinical antibody aimed at EGFR. The company's treatments are intended for people with solid tumors driven by RAS mutations, and it conducts research and trials mainly in the United States.
Based on the company's 10-K filed Mar 12, 2026.
Nasdaq · Healthcare
Erasca, Inc. (ERAS)
What Is the Price Target for ERAS?
SEPT Low Target
$20.00
SEPT Mid Target
$21.50
SEPT High Target
$30.00
Analyst Consensus
$21.50
Is ERAS a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ERAS.
Start Free Trial →Is ERAS Overvalued or Undervalued?
Valuation Verdict
OVERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$16.88
12
Moat Score
NONE
3/9
Piotroski Score
36.7
Altman Z-Score
What Is Smart Money Doing with ERAS?
Insider Signal
NEUTRAL
0 buys / 3 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →ERAS Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
36.23%
FCF Growth YoY
12.7%
Revenue Trend
UNKNOWN
Dark Pool Trades for ERAS
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for ERAS, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:58:56 | $15.78 | 40,241 | $$635K | SELL |
| 21:26:31 | $15.78 | 1,245 | $$20K | SELL |
| 21:00:40 | $15.78 | 1,200 | $$19K | SELL |
| 21:00:40 | $15.78 | 6,070 | $$96K | SELL |
| 21:00:40 | $15.78 | 14,511 | $$229K | SELL |
5 dark pool trades shown · $$998K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for ERAS
PREVIEWSEPT Investing provides real-time options flow tracking for ERAS, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $15 | Nov 20 | 8 | $$1680 | 7 | SWEEP |
| CALL | $20 | Nov 20 | 8 | $$180 | 6 | SWEEP |
| CALL | $17.5 | Nov 20 | 8 | $$1080 | 12 | SWEEP |
| CALL | $10 | Jan 15 | 64 | $$660 | 1 | SWEEP |
| CALL | $10 | Jan 15 | 64 | $$660 | 1 | SWEEP |
5 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Erasca, Inc. (ERAS) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →ERAS — frequently asked questions
What is ERAS stock price today?
Erasca, Inc. (ERAS) is at $15.78, down 6.07% (-$1.02) at the Nov 12, 2026 close.
Why is ERAS stock moving today?
Latest ERAS news — Nov 4, 2026: Tango Therapeutics and Erasca Start Combination Clinical Trial
What is the ERAS price target?
The average analyst price target for ERAS is $21.50, ranging from $20 to $30, based on 6 analysts. Latest: B of A Securities maintains on Aug 14, 2026.
What do analysts rate ERAS?
Analyst ratings for ERAS: 0 Buy, 8 Hold, 0 Sell — consensus Hold.
Did ERAS beat earnings?
ERAS last reported on Nov 12, 2026: EPS -$0.15 vs -$0.13 expected — a miss of 15.3%.
Does ERAS pay a dividend?
ERAS does not currently pay a dividend.
What are ERAS support and resistance levels?
Support: $15.38, $13.11, $11.80. Resistance: $16.88, $18.77, $20.40.
What are insiders doing with ERAS?
Insider activity: NEUTRAL, 0 buys and 3 sells in the last 90 days.
What is the latest news on ERAS?
Nov 4, 2026: Tango Therapeutics and Erasca Start Combination Clinical Trial